FOR IMMEDIATE RELEASE
Michelle McAdam, Chronic Communications
email@example.com, (310) 902-1274
NEW CLINICAL TRIAL AT LA BIOMED/HARBOR-UCLA AND USC OFFERS HOPE FOR EMPHYSEMA PATIENTS
Investigational Treatment May Help Lungs Function More Effectively Without Surgery, Enabling Better Breathing and Quality of Life
LOS ANGELES, Calif. – June 4, 2015 – A clinical trial for patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease (COPD), recently commenced at two Los Angeles medical centers to study a new, investigational treatment that may help them breathe easier without surgery. Keck Medicine of the University of Southern California (USC) and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center are the only centers in Los Angeles participating in this clinical trial, which is taking place at 12 other centers across the United States.
Emphysema affects more than four million people in the U.S. and is a progressive disease causing continual breathlessness for patients, even while at rest. Smokers or ex-smokers are most commonly affected by the disease, where portions of the lung are destroyed and air is trapped in pockets, hyperinflating localized regions in the lung. The hyperinflated portion of the lung compresses the healthy areas of the lung, making it difficult to breathe. The inability to breathe freely can drastically limit a patient’s stamina and activity level, as well as their quality of life.
Today, emphysema patients often use medication and/or inhalers to relieve symptoms, but the disease is progressive so their lungs continue to deteriorate over time. Severe emphysema patients have no commercially available alternatives except lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs.
The treatment being studied in the LIBERATE study is endobronchial lung volume reduction using the Zephyr® Endobronchial Valve. In those patients who are identified as potential responders, tiny one-way valves are placed in the lungs to block airflow to diseased regions of the lung. This allows healthy regions to expand and function more efficiently, enabling better breathing and improving quality of life. Minimally invasive surgery is involved in the procedure.
The principal investigator for the LIBERATE study at LA BioMed/Harbor-UCLA Medical Center is David Hsia, M.D., associate professor of medicine. The principal investigator for the LIBERATE Study at Keck Medicine of USC is P. Michael McFadden, M.D., professor of cardiothoracic surgery and surgical director of lung transplantation.
More than 25,000 Zephyr valves have been implanted outside of the U.S. in the last 10 years. Clinical studies in Europe have shown that the majority of patients who undergo the procedure experience significant improvement in lung function, exercise tolerance and quality of life. Results from the LIBERATE Study will be used as part of the submission seeking approval from the FDA.
For more information about the LIBERATE clinical trial, please visit www.pulmonx.com or call (888) 248-LUNG (5864).
CAUTION: The Zephyr Endobronchial Valve is an investigational device in the U.S., limited by U.S. law to investigational use.